IP Library › Granted Patent US 7,034,057

Granted Patent B2

US 7,034,057 · App. 10/716,890 · Granted Apr 25, 2006

Compounds for the treatment of inflammatory disorders

View Patent ↗

Loading inventors, assignments & file history…

Monitor This Case

Get email alerts when status or documents change.

Order Certified Copies

Most orders are placed with the USPTO same day — all within 24 business hours.

Order via The Patent Place →

Pre-filled with this patent's details

Quick Facts

Patent No.: US 7,034,057
App. No.: 10/716,890
Granted: Apr 25, 2006
Kind: B2

External Links

USPTO Patent Center↗ Full Patent PDF↗

Abstract

This invention relates to compounds of the Formula (I): or a pharmaceutically acceptable salt, solvate or isomer thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, TNF-α or combinations thereof.

Claims (80)

1. A method for treating inflammatory disorder associated with TACE (TNF-α) and/or MMP, consisting of Crohn's disease and colitis, osteo and rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, multiple sclerosis, osteoporosis, soriasis and atopidermatitis comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula (I):

or a pharmaceutically acceptable salt, solvate or isomer thereof, wherein:

M is —(C(R 30 )(R 40 )) m —, wherein m is 1;

T is selected from the group consisting of R 21 -substituted alkyl, cycloalkyl, heterocycloalkyl, cycloalkenyl, heterocycloalkenyl, aryl, heteroaryl, —OR 3 , —C(O)R 4 , —C(O)OR 3 , —C(O)NR 24 R 25 , —C(O)NR 24 OR 3 , —C(O)SR 3 , —NR 24 R 25 , —NR 25 C(O)R 4 , —NR 25 C(O)OR 3 , —NR 25 C(O)NR 24 R 25 , —NR 25 C(O)NR 24 OR 3 , —SR 3 , —S(O) x NR 24 R 25 , —S(O) x NR 25 OR 3 , —CN, —P(O)(R 24 )(OR 24 ), —P(O)(OR 24 )(OR 24 ), —C(R 4 )(═N(OR 3 )), —C(O)-AA-NR 24 R 25 and —C(O)-AA-NR 25 OR 3 ,

wherein each of the cycloalkyl, heterocycloalkyl, cycloalkenyl, heterocycloalkenyl, aryl and heteroaryl groups of T is independently unsubstituted or substituted with one to five independently selected R 20 moieties which can be the same or different, each R 20 moiety being independently selected from the group of R 20 moieties below;

V is selected from the group consisting of alkyl, R 21 -substituted alkyl, cycloalkyl, heterocycloalkyl, cycloalkenyl, heterocycloalkenyl, aryl, heteroaryl, —OR 3 , —C(O)R 4 , —(CR 23 R 24 ) n1 C(O)OR 3 , —C(O)NR 24 R 25 , —(CR 23 R 24 ) n1 C(O)NR 25 OR 3 , —C(O)SR 3 , —NR 24 R 25 , —NR 25 C(O)R 4 , —NR 25 C(O)OR 3 , —NR 25 C(O)NR 24 R 25 , —NR 25 C(O)NR 24 OR 3 , —SR 3 , —S(O) x NR 24 R 25 , —S(O) x NR 25 OR 3 , —CN, —P(O)(R 24 )(OR 24 ), —P(O)(OR 24 )(OR 24 ), —C(R 4 )(═N(OR 3 )), —C(O)-AA-NR 24 R 25 and —C(O)-AA-NR 25 OR 3 ,

wherein each of the cycloalkyl, heterocycloalkyl, cycloalkenyl, heterocycloalkenyl, aryl and heteroaryl groups of V is independently unsubstituted or substituted with one to three independently selected R 20 moieties which can be the same or different, each R 20 moiety being independently selected from the group of R 20 moieties below;

W is —(CH 2 )—;

X is unsubstituted phenyl;

U is —O—(CH 2 )—;

n is 0 to 2;

n1 is 0 to 2;

x is 0 to 2;

AA is

wherein R 31 and R 32 are the same or different and are each independently selected from the group consisting of H, alkyl, cycloalkyl, aryl, heteroaryl, —NR 24 R 25 , —(CH 2 ) 3 NH(C═NH)—NH 2 , —CH 2 C(O)—NH 2 , —CH 2 C(O)OH, —CH 2 SH, —CH 2 S—SCH 2 CH(NH 2 )C(O)OH, —CH 2 CH 2 C(O)OH, —CH 2 CH 2 C(O)NH 2 , —(CH 2 ) 4 NH 2 , —CH 2 CH 2 CH(OH)CH 2 NH 2 , —CH 2 CH(CH 3 ) 2 , —CH(CH 3 )CH 2 (CH 3 ), —CH 2 CH 2 SCH 3 , —CH 2 OH, —CH(OH)(CH 3 ),

or R 31 and R 32 , together with the N to which R 31 is attached and the C to which R 31 is attached, form a 5-membered ring which is unsubstituted or independently substituted with a hydroxyl group;

R 1 is selected from the group consisting of unsubstituted quinolyl, alkyl-substituted quinolyl and aryl-substituted quinolyl;

each R 2 , R 4 and R 5 is the same or different and each is independently selected from the group consisting of H, halo, alkyl, R 22 -substituted alkyl, cycloalkyl, heterocycloalkyl, cycloalkenyl, heterocycloalkenyl, aryl, heteroaryl, —OR 6 , —C(O)R 7 , —C(O)OR 6 , —NR 24 R 25 , —NR 24 C(O)R 25 , —N(═C—O—NR 24 R 25 ), —NR 24 S(O) 2 R 25 ,

wherein each of the cycloalkyl, heterocycloalkyl, cycloalkenyl, heterocycloalkenyl, aryl and heteroaryl groups of R 2 , R 4 and R 5 is independently unsubstituted or substituted with one to four independently selected alkyl, R 22 -substituted alkyl or R 22 moieties which can be the same or different, each R 22 moiety being independently selected from the group of R 22 moieties below;

each R 3 is the same or different and is independently selected from the group consisting of H, alkyl, R 22 -substituted alkyl, cycloalkyl, heterocycloalkyl, cycloalkenyl, heterocycloalkenyl, aryl, heteroaryl, —OR 6 , —C(O)R 7 , —C(O)OR 6 , —NR 24 R 25 , —NR 24 C(O)R 25 , —N(═C—O—NR 24 R 25 ) and —NR 24 S(O) 2 R 25 ,

each of the cycloalkyl, heterocycloalkyl, cycloalkenyl, heterocycloalkenyl, aryl and heteroaryl groups of R 3 is independently unsubstituted or substituted with one to four independently selected alkyl, R 22 -substituted alkyl or R 22 moieties which can be the same or different, each R 22 moiety being independently selected from the group of R 22 moieties below;

each R 6 is independently selected from the group consisting of H, alkyl and —OCF 3 ;

each R 7 is independently selected from the group consisting of H, alkyl, heteroaryl and —CF 3 ;

each R 20 is independently selected from the group consisting of: alkyl, R 21 -substituted alkyl, —OR 3 , halo, —CN, —NO 2 , —NR 24 R 25 , —C(O)R 3 , —C(O)OR 3 , —C(O)NR 24 R 25 , —S(O) x NR 24 R 25 , —S(O) x R 5 , —CF 3 , —OCF 3 , —C 2 CF 3 , —C(═NOH)R 3 , aryl, halo-substituted aryl, heteroaryl, cycloalkyl, heterocycloalkyl, —N(R 25 )S(O) x R 5 , —N(R 25 )C(O)R 5 , and —N(R 25 )C(O)NR 24 R 25 ,

wherein each of the aryl, halo-substituted aryl, heteroaryl, cycloalkyl and heterocycloalkyl groups of R 20 is independently unsubstituted or substituted with one to four independently selected R 22 moieties which can be the same or different, each R 22 moiety being independently selected from the group of R 23 moieties below,

or two R 20 groups taken together with the carbon to which both R 20 groups are attached is

R 21 is one to three substituents independently selected from the group consisting of: —OR 3 , halo, —CN, —NO 2 , —NR 24 R 25 , —C(O)R 3 , —C(O)OR 3 , —C(O)NR 24 R 25 , —S(O) x NR 24 R 25 , —SO x R 5 , —CF 3 , —OCF 3 , —CF 2 CF 3 , —C(═NOH)R 3 , R 23 -substituted alkyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, —N(R 25 )S(O) x R 5 , —N(R 25 )C(O)R 5 , and —N(R 25 )C(O)NR 24 R 25 ;

wherein each of the aryl, halo-substituted aryl, heteroaryl, cycloalkyl, and heterocycloalkyl groups of R 21 is independently unsubstituted or substituted with one to four independently selected R 23 moieties which can be the same or different, each R 23 moiety being independently selected from the group of R 23 moieties below,

or two R 21 groups taken together with the carbon to which both R 21 groups are attached is

each R 22 is independently selected from the group consisting of: halo, alkynyl, aryl, heteroaryl, —OR 24 , —C 1 –C 6 alkyl)—OR 24 , —CN, —NO 2 , —NR 24 R 25 , C(O)R 23 , —C(O)OR 23 , —C(O)NR 24 R 25 , —S(O) x NR 24 R 25 , —S(O) x R 23 , —CF 3 , —OCF 3 , —CF 2 CF 3 , —C(═NOH)R 23 , —N(R 24 )S(O) x R 25 , —N(R 24 )C(O)R 25 , and —N(R 24 )C(O)NR 24 R 25 ,

or two R 22 groups taken together with the carbon to which both R 22 groups are attached is

each R 23 is independently selected from the group consisting of H, hydroxyl, halo and alkyl;

each R 24 is independently selected from the group consisting of H and alkyl;

each R 25 is independently selected from the group consisting of H, hydroxyl, alkyl, hydroxyalkyl, aryl, cycloalkyl, heteroaryl, —NR 24 R 24 , —(C 1 to C 6 alkyl)NR 24 N 24 , —CF 3 and —S(O) x R 23 ;

each R 26 is independently selected from the group consisting of H, hydroxyl, alkyl, hydroxyalkyl, aryl, cycloalkyl, heteroaryl and —NR 3 R 4 ;

R 27 is independently selected from the group consisting of heteroaryl, heterocycloalkyl and —NR 24 R 25 ;

R 30 is independently selected from the group consisting of H and R 20 substituent groups above;

R 40 is independently selected from the group consisting of H and R 20 substituent groups above,

or R 30 and R 40 , taken together with the carbon to which R 30 and R 40 are attached, is

with the proviso that at least one of V or T is selected from the group consisting of —C(O)—N(R 3 )(OR 4 ), —C(O)OR 3 and —C(O)NR 24 R 25 .

2. A method of treating rheumatoid arthritis, osteoarthritis, periodontal disease, cancer or osteoporosis in a subject comprising: administering to the subject in need of such treatment a therapeutically effective amount of a compound of Formula (I):

or a pharmaceutically acceptable salt, solvate or isomer thereof, wherein:

M is —(C(R 30 )(R 40 )) m —, wherein m is 1;

T is selected from the group consisting of R 21 -substituted alkyl, cycloalkyl, heterocycloalkyl, cycloalkenyl, heterocycloalkenyl, aryl, heteroaryl, —OR 3 , —C(O)R 4 , —C(O)OR 3 , —C(O)NR 24 R 25 , —C(O)NR 24 OR 3 , —C(O)SR 3 , —NR 24 R 25 , —NR 25 C(O)R 4 , —NR 25 O(O)OR 3 , —NR 25 C(O)NR 24 R 25 , —NR 25 C(O)NR 24 OR 3 , —SR 3 , —S(O) x NR 24 R 25 , —S(O) x NR 25 OR 3 , —CN, —P(O)(R 24 )(OR 24 ), —P(O)(OR 24 )(OR 24 ), —C(R 4 )(═N(OR 3 )), —C(O)-AA-NR 24 R 25 and —C(O)-AA-NR 25 OR 3 ,

wherein each of the cycloalkyl, heterocycloalkyl, cycloal kenyl, heterocycloalkenyl, aryl and heteroaryl groups of V is independently unsubstituted or substituted with one to three independently selected R 20 moieties which can be the same or different, each R 20 moiety being independently selected from the group of R 20 moieties below;

W is —(CH 2 )—;

X is unsubstituted phenyl;

U is —O—(CH 2 )—;

n is 0 to 2;

n1 is 0 to 2;

x is 0 to 2;

AA is

wherein R 31 and R 32 are the same or different and are each independently selected from the group consisting of H, alkyl, cycloalkyl, aryl, heteroaryl, —NR 24 R 25 , —(CH 2 ) 3 NH(C═NH)NH 2 , —CH 2 C(O)NH 2 , —CH 2 C(O)OH, —CH 2 SH, —CH 2 S—SCH 2 CH(NH 2 )C(O)OH, —CH 2 CH 2 C(O)OH, —CH 2 CH 2 C(O)NH 2 , —(CH 2 ) 4 NH 2 , —CH 2 CH 2 CH(OH)CH 2 NH 2 , —CH 2 CH(CH 3 ) 2 , —CH(CH 3 )CH 2 (CH 3 ), —CH 2 CH 2 SCH 3 , —CH 2 OH, —CH(OH)(CH 3 ),

or R 31 and R 32 , together with the N to which R 31 is attached and the C to which R 31 is attached, form a 5-membered ring which is unsubstituted or independently substituted with a hydroxyl group;

R 1 is selected from the group consisting of unsubstituted quinolyl, alkyl-substituted quinolyl and aryl-substituted quinolyl;

each R 6 is independently selected from the group consisting of H, alkyl and —OCF 3 ;

each R 7 is independently selected from the group consisting of H, alkyl, heteroaryl and —CF 3 ;

each R 20 is independently selected from the group consisting of: alkyl, R 21 -substituted alkyl, —OR 3 , halo, —CN, —NO 2 , —NR 24 R 25 , —C(O)R 3 , —C(O)OR 3 , —C(O)NR 24 R 25 , —S(O) x NR 24 R 25 , —S(O) x R 5 , —CF 3 , —OCF 3 , —CF 2 CF 3 , —C(═NOH)R 3 , aryl, halo-substituted aryl, heteroaryl, cycloalkyl, heterocycloalkyl, —N(R 25 )S(O) x R 5 , —N(R 25 )C(O)R 5 , and —N(R 25 )C(O)NR 24 R 25 ,

or two R 20 groups taken together with the carbon to which both R 20 groups are attached is

or two R 21 groups taken together with the carbon to which both R 21 groups are attached is

each R 22 is independently selected from the group consisting of: halo, alkynyl, aryl, heteroaryl, OR 24 , —(C 1 –C 6 alkyl)—OR 24 , —CN, —NO 2 , —NR 24 R 25 , —C(O)R 23 , —C(O)OR 23 , —C(O)NR 24 R 25 , —S(O) x NR 24 R 25 , —S(O) x R 23 , —CF 3 , —OCF 3 , —CF 2 CF 3 , —C(═NOH)R 23 , —N(R 24 )S(O) x R 25 , —N(R 24 )—C(O)R 25 , and —N(R 24 )C(O)NR 24 R 25 ,